Novo Nordisk : invests DKK 800 million in upgrading and expanding production facilities in Kalundborg

Novo Nordisk invests DKK 800 million in upgrading and expanding production facilities in Kalundborg

Bagsværd, Denmark, 7 February 2020 - Novo Nordisk today announced plans to invest DKK 800 million in upgrading and expanding facilities at its production site in Kalundborg, Denmark.

The facilities currently manufacture a range of products for diabetes treatment and will be rebuilt and expanded to allow for future production of these products as well as the next generation of diabetes products. The projects are expected to be completed in 2022.

"This investment in our production facilities highlights our ambition to continue strengthening our presence in Denmark and Kalundborg. Today, we manufacture around half of the world's insulin in Kalundborg where we have been present for 50 years. Since the turn of the millennium alone, we have invested more than DKK 16 billion in these facilities, which are a cornerstone of our global production network", said Michael Hallgren, senior vice president for Novo Nordisk production in Kalundborg.

About Novo Nordisk Kalundborg

Established in 1969, the site covers a total area of 1,200,000 square metres and employs more than 3,000 people. Besides diabetes products a range of biopharmaceutical products are also produced at the production site in Kalundborg.

Visit novonordisk.com for photosand b-rollsupporting this press release.

Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 42,700 people in 80 countries and markets its products in more than 170 countries. For more information, visit novonordisk.com,Facebook,Twitter,LinkedIn,YouTube

Novo Nordisk A/S	Novo	Allé	Tel: [phone]	CVR no:
Corporate Communication	2880	Bagsværd	www.novonordisk.com	24 25 67 90
	Denmark

Page 2 of 2

Further information
Media:
Mette Kruse Danielsen	[phone]	[e-mail]
Ken Inchausti (US)	[phone]	[e-mail]
Investors:
Peter Hugreffe Ankersen	[phone]	[e-mail]
Valdemar Borum Svarrer	[phone]	[e-mail]
Ann Søndermølle Rendbæk	[phone]	[e-mail]
Mark Joseph Root	[phone]	[e-mail]
Kristoffer Due Berg (US)	[phone]	[e-mail]

Novo Nordisk A/S	Novo	Allé	Telephone:	Internet:
Corporate Affairs	2880	Bagsværd	[phone]	www.novonordisk.com
	Denmark		CVR no:
				24 25 67 90